Hepatitis C virus (HCV) infection is highly prevalent among individuals with chronic kidney disease (CKD) and is associated with worse health outcomes, including more rapid progression to end-stage kidney disease, higher mortality on dialysis therapy, and among those receiving a kidney transplant, increased risk for posttransplantation diabetes and decreased patient and allograft survival. Before the introduction of highly effective direct-acting antivirals in 2013, prolonged therapy with interferon and ribavirin was standard of care, and eradication of HCV was rare in patients with end-stage kidney disease.